Antibodies against type I IFN: The bad guys self-restrain in systemic lupus erythematosus

Simon Fillatreau

doi:10.1016/j.xcrm.2022.100903

Antibodies against type I IFN: The bad guys self-restrain in systemic lupus erythematosus

Cell Rep Med. 2023 Jan 17;4(1):100903. doi: 10.1016/j.xcrm.2022.100903.

Author

Simon Fillatreau¹

Affiliation

¹ Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, F-75015 Paris, France; Service Immunologie Biologique, AP-HP, Hôpital Necker-Enfants Malades, F-75015 Paris, France. Electronic address: simonfillatreau@googlemail.com.

Abstract

B cells and autoantibodies have well-described pathological roles in systemic lupus erythematosus (SLE). Bradford et al.¹ now provide evidence that autoantibodies can also be protective by neutralizing type I interferons (IFNs) and restraining the activation of pathogenic B cells.

Publication types

Comment

MeSH terms

Autoantibodies
B-Lymphocytes
Humans
Interferon Type I*
Lupus Erythematosus, Systemic*
Male

Substances

Interferon Type I
Autoantibodies